CENTESSA PHARMACEUTICALS PLC (CNTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$40.500.00%
Close 2026-06-25 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CNTA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-07-02.
The screen ranks CNTA against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finalize the acquisition transaction with Eli Lilly and integrate operations as a wholly owned subsidiary.
Stated as a priority in 3 of last 3 quarters. The acquisition by Eli Lilly was completed on June 24, 2026, following the March 31, 2026 Transaction Agreement. The company expected cash to fund operations into mid-2027 as of late 2025. The trajectory shows delivery of the acquisition milestone.
“Completed the acquisition transactions with Eli Lilly and LDH XV Corporation on June 24, 2026.”
“Entered into a Transaction Agreement with Eli Lilly and LDH XV Corporation on March 31, 2026.”
“The Company expects its cash, cash equivalents and investments as of September 30, 2025 will fund operations into mid-2027.”
Manage leadership transition with appointment of Dr. Mario Alberto Accardi as CEO and Board member.
Stated as a priority in 3 of last 3 quarters. The CEO transition was completed with Dr. Accardi's appointment in early 2026, following Dr. Saha's departure. Multiple senior executives also departed due to the acquisition. The leadership change is fully executed.
“Multiple senior executives and directors departed due to the Acquisition.”
Maintain sufficient liquidity to fund operations through mid-2027 amid ongoing operating losses and negative cash flow.
Newly stated in 2025-Q4. The company expects cash to fund operations into mid-2027 as of September 30, 2025. Operating cash flow was negative $72.2M and net income negative $79.2M in 2026-Q1, reflecting ongoing cash burn. The trajectory shows continued operating losses with liquidity guidance supporting funding through mid-2027.
“The Company expects its cash, cash equivalents and investments as of September 30, 2025 will fund operations into mid-2027.”
Over the trailing year it converted 1.10x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
19 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.
“Dr. Mario Alberto Accardi was appointed as the new CEO and joined the Board of Directors.”
“Dr. Saurabh Saha stepped down from his position as CEO and Board member.”